Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’s Proprietary Drug for Treatment of Obstructive Sleep Apnoea (‘OSA’)

Incannex Healthcare Limited has received approval from the Bellberry Human Research Ethics Committee to conduct a bioequivalence/bioavailability clinical trial for their proprietary drug, IHL-42X. This drug is specifically designed for the treatment of obstructive sleep apnoea (OSA). The trial will involve 116 participants and will be managed by Novotech at CMAX Clinical Research in South Austra..